SNAP25

Synaptosome associated protein 25

Score: 0.484 Price: $0.48 Low Druggability Status: active Wiki: SNAP25

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

215

DEBATES

3D Protein Structure

🧬 SNAP25 — PDB 1KIL Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.33

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.20

Druggability Analysis

Drug Development0.75

Structural Tractability0.85

Target Class0.50

Safety Profile0.20

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (1 compounds)

1 Approved

Druggability Rationale: SNAP25 presents medium druggability with validated proof-of-concept from approved botulinum toxin therapeutics, supported by 49 PDB structures at 1.5Å resolution and AlphaFold modeling. However, as a structural protein mediating protein-protein interactions within the SNARE complex, direct small molecule inhibition faces challenges in achieving specificity and sufficient binding affinity to compete with native protein-protein interactions.

Mechanism: Protein cleavage by botulinum toxin or small molecule modulators of SNARE complex formation

Drug Pipeline (1 compounds)

1 Approved

Known Drugs:

Botulinum toxin A (approved) — Movement disorders, spasticity

Structural Data:

PDB (49) ✓AlphaFold ✓Cryo-EM —

1XTG 2N1T 3DDB 3HD7 3J96+44 more

UniProt: P60880

🧬 3D Protein Structure

🧬 SNAP25 — PDB 1KIL Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

SNAP25 selectivity is complicated by its structural homologs SNAP23 and SNAP29, which share significant sequence identity and could lead to off-target engagement. Achieving isoform selectivity through small molecules targeting the SNARE-binding interface will require structure-guided design to exploit subtle conformational differences.